Literature DB >> 9380718

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis.

R Aharoni1, D Teitelbaum, M Sela, R Arnon.   

Abstract

The synthetic amino acid copolymer copolymer 1 (Cop 1) suppresses experimental autoimmune encephalomyelitis (EAE) and is beneficial in multiple sclerosis. To further understand Cop 1 suppressive activity, we studied the cytokine secretion profile of various Cop 1-induced T cell lines and clones. Unlike T cell lines induced by myelin basic protein (MBP), which secreted either T cell helper type 1 (Th1) or both Th1 and Th2 cytokines, the T cell lines/clones induced by Cop 1 showed a progressively polarized development toward the Th2 pathway, until they completely lost the ability to secrete Th1 cytokines. Our findings indicate that the polarization of the Cop 1-induced lines did not result from the immunization vehicle or the in vitro growing conditions, but rather from the tendency of Cop 1 to preferentially induce a Th2 response. The response of all of the Cop 1 specific lines/clones, which were originated in the (SJL/JxBALB/c)F1 hybrids, was restricted to the BALB/c parental haplotype. Even though the Cop 1-induced T cells had not been exposed to the autoantigen MBP, they crossreacted with MBP by secretion of interleukin (IL)-4, IL-6, and IL-10. Administration of these T cells in vivo resulted in suppression of EAE induced by whole mouse spinal cord homogenate, in which several autoantigens may be involved. Secretion of anti-inflammatory cytokines by Cop 1-induced suppressor cells, in response to either Cop 1 or MBP, may explain the therapeutic effect of Cop 1 in EAE and in multiple sclerosis.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9380718      PMCID: PMC23498          DOI: 10.1073/pnas.94.20.10821

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  29 in total

1.  Basic encephalitogenic protein: A simplified purification on sulphoethyl-sephadex.

Authors:  H Hirshfeld; D Teitelbaum; R Arnon; M Sela
Journal:  FEBS Lett       Date:  1970-05-01       Impact factor: 4.124

Review 2.  TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties.

Authors:  T R Mosmann; R L Coffman
Journal:  Annu Rev Immunol       Date:  1989       Impact factor: 28.527

3.  Suppression of experimental allergic encephalomyelitis by a synthetic polypeptide.

Authors:  D Teitelbaum; A Meshorer; T Hirshfeld; R Arnon; M Sela
Journal:  Eur J Immunol       Date:  1971-08       Impact factor: 5.532

Review 4.  Th1 and Th2 CD4+ T cells in the pathogenesis of organ-specific autoimmune diseases.

Authors:  R S Liblau; S M Singer; H O McDevitt
Journal:  Immunol Today       Date:  1995-01

5.  Molecular requirements involved in suppression of EAE by synthetic basic copolymers of amino acids.

Authors:  C Webb; D Teitelbaum; A Herz; R Arnon; M Sela
Journal:  Immunochemistry       Date:  1976-04

Review 6.  Manipulation of the Th1/Th2 balance in autoimmune disease.

Authors:  L B Nicholson; V K Kuchroo
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

Review 7.  Cytokines in autoimmunity.

Authors:  F M Brennan; M Feldmann
Journal:  Curr Opin Immunol       Date:  1996-12       Impact factor: 7.486

8.  Analysis of cytokine mRNA expression in the central nervous system of mice with experimental autoimmune encephalomyelitis reveals that IL-10 mRNA expression correlates with recovery.

Authors:  M K Kennedy; D S Torrance; K S Picha; K M Mohler
Journal:  J Immunol       Date:  1992-10-01       Impact factor: 5.422

9.  T suppressor hybridomas and interleukin-2-dependent lines induced by copolymer 1 or by spinal cord homogenate down-regulate experimental allergic encephalomyelitis.

Authors:  R Aharoni; D Teitelbaum; R Arnon
Journal:  Eur J Immunol       Date:  1993-01       Impact factor: 5.532

10.  Patterns of cytokine secretion by autoreactive proteolipid protein-specific T cell clones during the course of multiple sclerosis.

Authors:  J Correale; W Gilmore; M McMillan; S Li; K McCarthy; T Le; L P Weiner
Journal:  J Immunol       Date:  1995-03-15       Impact factor: 5.422

View more
  75 in total

Review 1.  Oral tolerance with copolymer 1 for the treatment of multiple sclerosis.

Authors:  H L Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-03-30       Impact factor: 11.205

Review 2.  Immunologic therapy for relapsing-remitting multiple sclerosis.

Authors:  H J MacLean; M S Freedman
Journal:  Curr Neurol Neurosci Rep       Date:  2001-05       Impact factor: 5.081

Review 3.  Peptide-based immunotherapy of autoimmunity: a path of puzzles, paradoxes and possibilities.

Authors:  S M Anderton
Journal:  Immunology       Date:  2001-12       Impact factor: 7.397

4.  Specific Th2 cells accumulate in the central nervous system of mice protected against experimental autoimmune encephalomyelitis by copolymer 1.

Authors:  R Aharoni; D Teitelbaum; O Leitner; A Meshorer; M Sela; R Arnon
Journal:  Proc Natl Acad Sci U S A       Date:  2000-10-10       Impact factor: 11.205

Review 5.  First-line disease-modifying therapies in paediatric multiple sclerosis: a comprehensive overview.

Authors:  Jessica Johnston; Tsz-Yin So
Journal:  Drugs       Date:  2012-06-18       Impact factor: 9.546

6.  Glatiramer acetate induced acute exacerbation of autoimmune hepatitis in a patient with multiple sclerosis.

Authors:  Helmut Neumann; Antal Csepregi; Michael Sailer; Peter Malfertheiner
Journal:  J Neurol       Date:  2007-03-12       Impact factor: 4.849

7.  Induction and blockage of oligodendrogenesis by differently activated microglia in an animal model of multiple sclerosis.

Authors:  Oleg Butovsky; Gennady Landa; Gilad Kunis; Yaniv Ziv; Hila Avidan; Nadav Greenberg; Adi Schwartz; Igor Smirnov; Ayala Pollack; Steffen Jung; Michal Schwartz
Journal:  J Clin Invest       Date:  2006-03-23       Impact factor: 14.808

8.  The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis.

Authors:  N N Spirin; D S Kasatkin
Journal:  Neurosci Behav Physiol       Date:  2009-01

9.  Nasal vaccination with a proteosome-based adjuvant and glatiramer acetate clears beta-amyloid in a mouse model of Alzheimer disease.

Authors:  Dan Frenkel; Ruth Maron; David S Burt; Howard L Weiner
Journal:  J Clin Invest       Date:  2005-08-11       Impact factor: 14.808

10.  Glatiramer acetate guards against rapid memory decline during relapsing-remitting experimental autoimmune encephalomyelitis.

Authors:  Patrizia LoPresti
Journal:  Neurochem Res       Date:  2014-12-07       Impact factor: 3.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.